Otto U, Schneider A, Denkhaus H, Conrad S
Urologische Universitätsklinik, Hamburg.
Onkologie. 1988 Aug;11(4):185-91. doi: 10.1159/000216519.
In a phase-II and a phase-III study patients with histopathologically documented metastatic renal cell carcinoma were treated either with gamma-interferon in two different doses (100 micrograms/m2 3x/week for 4 h i.v. every other week or 500 micrograms/m2 5x/week for 24 h i.v. every other week) or with alpha-2-interferon alone (18 x 10(6) U 3x/week weekly i.m.) or in combination with vinblastine (0.1 mg/kg every third week i.v.). The purpose of these studies was to evaluate the response rate, the duration of response, the survival, the efficacy and the toxicity of the different forms of treatment. The overall response rate to gamma-interferon was 30% in both regimens. The response rate of treatment with alpha-2-interferon was found to be 31%. The duration of response ranged between 2 and 34+ months in patients treated with gamma-interferon and between 2 and 24+ months in those receiving alpha-2-interferon. Patients with objective tumor response showed a significantly longer survival than those not responding (p = 0.0056). Low-dose-gamma-interferon and alpha-2-interferon treatment could be easily done on an outpatient basis. In conclusion, interferon treatment seems to be of value in the therapy of patients with well documented progressive disease in metastatic renal cell cancer.
在一项II期和一项III期研究中，对组织病理学确诊的转移性肾细胞癌患者进行了治疗，治疗方式包括两种不同剂量的γ干扰素（100微克/平方米，每周3次，每次静脉注射4小时，每隔一周一次；或500微克/平方米，每周5次，每次静脉注射24小时，每隔一周一次），或单独使用α-2干扰素（18×10⁶单位，每周肌肉注射3次），或与长春碱联合使用（每三周静脉注射0.1毫克/千克）。这些研究的目的是评估不同治疗方式的缓解率、缓解持续时间、生存率、疗效和毒性。两种γ干扰素治疗方案的总体缓解率均为30%。α-2干扰素治疗的缓解率为31%。接受γ干扰素治疗的患者缓解持续时间为2至34多个月，接受α-2干扰素治疗的患者为2至24多个月。有客观肿瘤缓解的患者生存率明显长于无缓解患者（p = 0.0056）。低剂量γ干扰素和α-2干扰素治疗可在门诊轻松进行。总之，干扰素治疗似乎对有充分记录的转移性肾细胞癌进展性疾病患者的治疗有价值。
